A Phase 2 Study to Evaluate the Safety and Efficacy of Telisotuzumab Adizutecan for the Treatment of Subjects with Locally Advanced or Metastatic Solid Tumors that Harbor MET Amplification

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518871-74-00

Enrollment

Registered

2026-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2026-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced or Metastatic Solid Tumours that harbour MET Amplification gene

Brief summary

Confirmed Objective Response (OR) as Assessed by Independent Central Review (ICR)

Detailed description

Duration of Response (DoR) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Progression-Free Survival (PFS) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Disease Control (DC) as Assessed by ICR based on RECIST v1.1 or RANO criteria as appropriate to tumor type in subjects with MET amplified positivity determined by F1CDx testing, OS in Participants with MET Amplified Positivity Determined by F1CDx Testing

Interventions

DRUGTelisotuzumab adizutecan

Eligibility

Sex/Gender

All

Age

0 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Confirmed Objective Response (OR) as Assessed by Independent Central Review (ICR)	—

Secondary

Measure	Time frame
Duration of Response (DoR) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Progression-Free Survival (PFS) as Assessed by ICR in participants with MET amplified positivity determined by F1CDx testing, Disease Control (DC) as Assessed by ICR based on RECIST v1.1 or RANO criteria as appropriate to tumor type in subjects with MET amplified positivity determined by F1CDx testing, OS in Participants with MET Amplified Positivity Determined by F1CDx Testing	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: May 19, 2026